» Articles » PMID: 20706991

Hyaluronan Inhibits Matrix Metalloproteinase-13 in Human Arthritic Chondrocytes Via CD44 and P38

Overview
Journal J Orthop Res
Publisher Wiley
Specialty Orthopedics
Date 2010 Aug 14
PMID 20706991
Citations 46
Authors
Affiliations
Soon will be listed here.
Abstract

We investigated the effects of hyaluronan (HA) on interleukin-1β (IL-1β)-stimulated matrix metalloproteinase (MMP)-13 production in human chondrocytes from patients with osteoarthritis (OA) or rheumatoid arthritis (RA). Secreted levels of MMP-13 in conditioned media were detected by immunoblotting, while intracellular MMP-13 synthesis in articular cartilage was evaluated by immunofluorescence microscopic analysis. Mitogen-activated protein kinases (MAPKs), p38, extracellular signal-regulated kinases (ERK), and c-jun NH2-terminal kinase (JNK) were assessed by Western blotting. IL-1β (2 ng/ml) stimulates the secretion of MMP-13 in both OA and RA chondrocytes. Inhibition studies using specific MAPK inhibitors revealed that IL-1β induced MMP-13 via p38 in both OA and RA chondrocytes. HA down-regulates IL-1β-stimulated MMP-13 and phosphorylated p38 (p-p38) in a dose-dependent manner (0.1, 1, 2, and 4 mg/ml). When used at 4 mg/ml, HA inhibits p-p38 phosphorylation by more than 60%. In response to IL-1β, RA chondrocytes express a higher level of p-p38 than that of OA chondrocytes. Inhibition of CD44, using a blocking antibody, significantly reversed the inhibitory effect of HA on both MMP-13 and p-p38. Our study clearly shows that HA inhibits IL-1β-induced MMP-13 via its principal receptor, CD44, and subsequent intracellular p38 MAPK signaling in OA and RA chondrocytes.

Citing Articles

Facile fabrication of chitosan/hyaluronic acid hydrogel-based wound closure material Co-loaded with gold nanoparticles and fibroblast growth factor to improve anti-microbial and healing efficiency in diabetic wound healing and nursing care.

Liu X, Peng S, Pei Y, Huo Y, Zong Y, Ren J Regen Ther. 2024; 26:1018-1029.

PMID: 39553541 PMC: 11565426. DOI: 10.1016/j.reth.2024.10.003.


An Advanced Mechanically Active Osteoarthritis-on-Chip Model to Test Injectable Therapeutic Formulations: The SYN321 Case Study.

Palma C, Piazza S, Visone R, Ringom R, Bjorklund U, Bermejo Gomez A Adv Healthc Mater. 2024; 13(32):e2401187.

PMID: 39318108 PMC: 11670293. DOI: 10.1002/adhm.202401187.


Effects of Diclofenac Etalhyaluronate (SI-613/ONO-5704) on Cartilage Degeneration in Arthritic Rats and Inflammatory Cytokine-Stimulated Human Chondrocytes.

Takada S, Nodera R, Yoshioka K Cartilage. 2024; :19476035231224050.

PMID: 38317317 PMC: 11569655. DOI: 10.1177/19476035231224050.


Predictors of Clinical Benefit with Intra-articular Hyaluronic Acid in Patients with Knee Osteoarthritis - A Narrative Review.

Chevalier X, Sheehan B Curr Rheumatol Rev. 2024; 20(4):379-387.

PMID: 38243964 PMC: 11275314. DOI: 10.2174/0115733971274662240108074038.


Osteopontin (OPN) alleviates the progression of osteoarthritis by promoting the anabolism of chondrocytes.

Luo W, Lin Z, Yuan Y, Wu Z, Zhong W, Liu Q Genes Dis. 2023; 10(4):1714-1725.

PMID: 37397527 PMC: 10311054. DOI: 10.1016/j.gendis.2022.08.010.